Sage Therapeutics Inc. said the U.S. Food and Drug Administration granted priority review to its new drug application for brexanolone, a medicine for postpartum depression.
Postpartum depression is a major depressive disorder that is the most common medical complication of childbirth, affecting a subset of women typically commencing in the third trimester of pregnancy or within four weeks after giving birth.
The Cambridge, Mass.-based company said the FDA will make a decision on the application by Dec. 19.
